์—ฐ๊ตฌ์šฉ

Pinometostat (EPZ5676) DOT1L inhibitor

์ œํ’ˆ ๋ฒˆํ˜ธS7062

Pinometostat (EPZ5676) is an S-adenosyl methionine (SAM) competitive inhibitor of protein methyltransferase DOT1L with Ki of 80 pM in a cell-free assay, demonstrating >37,000-fold selectivity against all other PMTs tested, inhibits H3K79 methylation in tumor. Phase 1.
Pinometostat (EPZ5676) Histone Methyltransferase inhibitor Chemical Structure

ํ™”ํ•™ ๊ตฌ์กฐ

๋ถ„์ž๋Ÿ‰: 562.71

๋ฐ”๋กœ๊ฐ€๊ธฐ

ํ’ˆ์งˆ ๊ด€๋ฆฌ (Quality Control)

๋ฐฐ์น˜: ์ˆœ๋„: 99.99%
99.99

ํ•จ๊ป˜ ์ž์ฃผ ์‚ฌ์šฉ๋˜๋Š” ์ œํ’ˆ Pinometostat (EPZ5676)

Bay K 8644

Among other factors, it and Bay K 8644 combine to create a cocktail that promotes the maturation of neurons in 3D cortical organoids.

GSK2879552 Dihydrochloride

Among other factors, this compound and GSK2879552 combine to create a cocktail that promotes the maturation of neurons in 3D cortical organoids.

NMDA (N-Methyl-D-aspartic acid)

Among other factors, it and NMDA combine to create a cocktail that promotes the maturation of neurons in 3D cortical organoids.

์„ธํฌ ๋ฐฐ์–‘, ์ฒ˜๋ฆฌ ๋ฐ ์ž‘์—… ๋†๋„
(Cell Culture, Treatment & Working Concentration)

์„ธํฌ์ฃผ ๋ถ„์„ ์œ ํ˜• ๋†๋„ ๋ฐฐ์–‘ ์‹œ๊ฐ„ ์ œํ˜• ํ™œ์„ฑ ์„ค๋ช… PMID
MV4-11 Function assay 4 days Inhibition of DOT1L in human MV4-11 cells expressing MLL-AF4 assessed as reduction of H3K79me2 level after 4 days by ELISA method 25406853
MOLM13 Proliferation assay Antiproliferative activity against human MOLM13 cells containing MLL-AF9, EC50=4 nM 23879463
MV4-11 Proliferation assay Antiproliferative activity against human MV4-11 cells containing MLL-AF4, EC50=4 nM 23879463
THP1 Proliferation assay Antiproliferative activity against human THP1 cells containing MLL-AF9, EC50=4 nM 23879463
HeLa Function assay 72 hrs Inhibition of DOT1L in human HeLa cells assessed as reduction in H3K79me2 level after 72 hrs by ELISA, IC50 = 0.007 ฮผM. 28337327
MV4-11 Antiproliferative assay 6 hrs Antiproliferative activity against human MV4-11 cells harboring MLL-AF4 treated for 6 hrs measured after 8 days by Celltiter-Glo reagent based assay, IC50 = 0.015 ฮผM. 28337327
MOLM13 Function assay 72 hrs Inhibition of DOT1L in human MOLM13 cells assessed as suppression of HoxA9 gene after 72 hrs by luciferase reporter gene assay, IC50 = 0.052 ฮผM. 28337327
ํด๋ฆญํ•˜์—ฌ ๋” ๋งŽ์€ ์„ธํฌ์ฃผ ์‹คํ—˜ ๋ฐ์ดํ„ฐ ๋ณด๊ธฐ

ํ™”ํ•™ ์ •๋ณด, ๋ณด๊ด€ ๋ฐ ์•ˆ์ •์„ฑ (Chemical Information, Storage & Stability)

๋ถ„์ž๋Ÿ‰ 562.71 ํ™”ํ•™์‹

C30H42N8O3

๋ณด๊ด€ (์ˆ˜๋ น์ผ๋กœ๋ถ€ํ„ฐ)
CAS ๋ฒˆํ˜ธ 1380288-87-8 SDF ๋‹ค์šด๋กœ๋“œ ์›์•ก ๋ณด๊ด€

๋™์˜์–ด N/A Smiles CC(C)N(CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C

์šฉํ•ด๋„ (Solubility)

In vitro
๋ฐฐ์น˜:

DMSO : 100 mg/mL (177.71 mM)
(์ˆ˜๋ถ„์œผ๋กœ ์˜ค์—ผ๋œ DMSO๋Š” ์šฉํ•ด๋„๋ฅผ ๊ฐ์†Œ์‹œํ‚ฌ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ์‹ ์„ ํ•˜๊ณ  ๋ฌด์ˆ˜ DMSO๋ฅผ ์‚ฌ์šฉํ•˜์‹ญ์‹œ์˜ค.)

Ethanol : 25 mg/mL

Water : Insoluble

๋ชฐ๋†๋„ ๊ณ„์‚ฐ๊ธฐ

์งˆ๋Ÿ‰ ๋†๋„ ๋ถ€ํ”ผ ๋ถ„์ž๋Ÿ‰
ํฌ์„ ๊ณ„์‚ฐ๊ธฐ ๋ถ„์ž๋Ÿ‰ ๊ณ„์‚ฐ๊ธฐ

In vivo
๋ฐฐ์น˜:

์ƒ์ฒด ๋‚ด ์ œํ˜• ๊ณ„์‚ฐ๊ธฐ (ํˆฌ๋ช…ํ•œ ์šฉ์•ก)

1๋‹จ๊ณ„: ์•„๋ž˜ ์ •๋ณด ์ž…๋ ฅ (๊ถŒ์žฅ: ์‹คํ—˜ ์ค‘ ์†์‹ค์„ ๊ณ ๋ คํ•˜์—ฌ ์ถ”๊ฐ€ ๋™๋ฌผ ํฌํ•จ)

mg/kg g ฮผL

2๋‹จ๊ณ„: ์ƒ์ฒด ๋‚ด ์ œํ˜• ์ž…๋ ฅ (์ด๊ฒƒ์€ ๊ณ„์‚ฐ๊ธฐ์ผ ๋ฟ ์ œํ˜•์ด ์•„๋‹™๋‹ˆ๋‹ค. ์šฉํ•ด๋„ ์„น์…˜์— ์ƒ์ฒด ๋‚ด ์ œํ˜•์ด ์—†๋Š” ๊ฒฝ์šฐ ๋จผ์ € ๋‹น์‚ฌ์— ๋ฌธ์˜ํ•˜์‹ญ์‹œ์˜ค.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

๊ณ„์‚ฐ ๊ฒฐ๊ณผ:

์ž‘์—… ๋†๋„: mg/ml;

DMSO ์›์•ก ์ค€๋น„ ๋ฐฉ๋ฒ•: mg ์•ฝ๋ฌผ ์‚ฌ์ „ ์šฉํ•ด ฮผL DMSO ( ์›์•ก ๋†๋„ mg/mL, ๋†๋„๊ฐ€ ํ•ด๋‹น ์•ฝ๋ฌผ ๋ฐฐ์น˜์˜ DMSO ์šฉํ•ด๋„๋ฅผ ์ดˆ๊ณผํ•˜๋Š” ๊ฒฝ์šฐ ๋จผ์ € ๋‹น์‚ฌ์— ๋ฌธ์˜ํ•˜์‹ญ์‹œ์˜ค. )

์ƒ์ฒด ๋‚ด ์ œํ˜• ์ค€๋น„ ๋ฐฉ๋ฒ•: ์ทจํ•˜๋‹ค ฮผL DMSO ์›์•ก, ๋‹ค์Œ ์ถ”๊ฐ€ฮผL PEG300, ํ˜ผํ•ฉํ•˜๊ณ  ํˆฌ๋ช…ํ•˜๊ฒŒ ํ•œ ๋‹ค์Œ ์ถ”๊ฐ€ฮผL Tween 80, ํ˜ผํ•ฉํ•˜๊ณ  ํˆฌ๋ช…ํ•˜๊ฒŒ ํ•œ ๋‹ค์Œ ์ถ”๊ฐ€ ฮผL ddH2O, ํ˜ผํ•ฉํ•˜๊ณ  ํˆฌ๋ช…ํ•˜๊ฒŒ ํ•ฉ๋‹ˆ๋‹ค.

์ƒ์ฒด ๋‚ด ์ œํ˜• ์ค€๋น„ ๋ฐฉ๋ฒ•: ์ทจํ•˜๋‹ค ฮผL DMSO ์›์•ก, ๋‹ค์Œ ์ถ”๊ฐ€ ฮผL ์˜ฅ์ˆ˜์ˆ˜ ๊ธฐ๋ฆ„, ํ˜ผํ•ฉํ•˜๊ณ  ํˆฌ๋ช…ํ•˜๊ฒŒ ํ•ฉ๋‹ˆ๋‹ค.

์ฐธ๊ณ : 1. ๋‹ค์Œ ์šฉ๋งค๋ฅผ ์ถ”๊ฐ€ํ•˜๊ธฐ ์ „์— ์•ก์ฒด๊ฐ€ ํˆฌ๋ช…ํ•œ์ง€ ํ™•์ธํ•˜์‹ญ์‹œ์˜ค.
2. ์šฉ๋งค๋ฅผ ์ˆœ์„œ๋Œ€๋กœ ์ถ”๊ฐ€ํ•ด์•ผ ํ•ฉ๋‹ˆ๋‹ค. ๋‹ค์Œ ์šฉ๋งค๋ฅผ ์ถ”๊ฐ€ํ•˜๊ธฐ ์ „์— ์ด์ „ ์ถ”๊ฐ€์—์„œ ์–ป์€ ์šฉ์•ก์ด ํˆฌ๋ช…ํ•œ ์šฉ์•ก์ธ์ง€ ํ™•์ธํ•ด์•ผ ํ•ฉ๋‹ˆ๋‹ค. ์™€๋™, ์ดˆ์ŒํŒŒ ๋˜๋Š” ๋œจ๊ฑฐ์šด ๋ฌผ ์ค‘ํƒ•๊ณผ ๊ฐ™์€ ๋ฌผ๋ฆฌ์  ๋ฐฉ๋ฒ•์„ ์‚ฌ์šฉํ•˜์—ฌ ์šฉํ•ด๋ฅผ ๋„์šธ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ž‘์šฉ ๋ฉ”์ปค๋‹ˆ์ฆ˜ (Mechanism of Action)

Targets/IC50/Ki
DOT1L
(Cell-free assay)
80 pM(Ki)
์‹œํ—˜๊ด€ ๋‚ด(In vitro)

EPZ-5676 reduces H3K79 dimethylation with a cellular IC50 of 2.6 nM in MV4-11 cells. EPZ-5676 treatment results in concentration- and time-dependent reduction of H3K79 methylation without effect on the methylation status of other histone sites, which leads to inhibition of key MLL target genes and selective, apoptotic cell killing in MLL-rearranged leukemia cells. EPZ-5676 inhibits proliferation of MLL-AF4 rearranged cell line MV4-11 with an IC50 of 9 nM.

์ƒ์ฒด ๋‚ด(In vivo)

EPZ-5676 continuously intravenous infusion for 21 days to xenograft model of MLL-rearranged leukemia, leads to dose-dependent anti-tumor activity. At the highest dose of 70.5 mg/kg/day, complete tumor regressions are achieved with no regrowth for up to 32 days after the cessation of treatment. No significant weight loss or obvious toxicity is observed in rats treated with EPZ-5676 during efficacy study.

์ฐธ์กฐ

์ ์šฉ ๋ถ„์•ผ (Applications)

๋ฐฉ๋ฒ• ๋ฐ”์ด์˜ค๋งˆ์ปค ์ด๋ฏธ์ง€ PMID
Western blot p-p65 / p65 / NFATc1 CDK6 / BCL11A / Bcl-2 / RUNX1 / MEF2C / H3K79me3 / H4
S7062-WB1
29348610
Immunofluorescence NFATc1
S7062-IF1
29348610

์ž„์ƒ์‹œํ—˜ ์ •๋ณด (Clinical Trial Information)

(๋ฐ์ดํ„ฐ ์ถœ์ฒ˜ https://clinicaltrials.gov, ์—…๋ฐ์ดํŠธ ๋‚ ์งœ 2024-05-22)

NCT ๋ฒˆํ˜ธ ๋ชจ์ง‘ ์กฐ๊ฑด ์Šคํฐ์„œ/ํ˜‘๋ ฅ์ž ์‹œ์ž‘์ผ ๋‹จ๊ณ„
NCT02141828 Completed
Leukemia|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Acute Leukemias
Epizyme Inc.|Celgene Corporation|Ipsen
May 2014 Phase 1
NCT01684150 Completed
Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome|Myeloproliferative Disorders
Epizyme Inc.|Celgene|Ipsen
September 2012 Phase 1

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ (Frequently Asked Questions)

์งˆ๋ฌธ 1:
Is the vehicle 30% PEG400/0.5% Tween80/5% propylene glycol recommended for in vivo use?

๋‹ต๋ณ€:
S7062 in 30% PEG400/0.5% Tween80/5% propylene glycol at 30 mg/ml is a suspension. For injection, 2% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml is suitable.